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Background and aims: Subendothelial interaction of LDL with extracellular matrix drives atherogenesis.
This interaction can be strengthened by proteolytic modification of LDL. Mast cells (MCs) are present in
atherosclerotic lesions, and upon activation, they degranulate and release a variety of neutral proteases.
Here we studied the ability of MC proteases to cleave apoB-100 of LDL and affect the binding of LDL to
proteoglycans.
Methods: Mature human MCs were differentiated from human peripheral blood-derived CD34þ pro-
genitors in vitro and activated with calcium ionophore to generate MC-conditioned medium. LDL was
incubated in the MC-conditioned medium or with individual MC proteases, and the binding of native and
modified LDL to isolated human aortic proteoglycans or to human atherosclerotic plaques ex vivo was
determined. MC proteases in atherosclerotic human coronary artery lesions were detected by immu-
nofluorescence and qPCR.
Results: Activated human MCs released the neutral proteases tryptase, chymase, carboxypeptidase A3,
cathepsin G, and granzyme B. Of these, cathepsin G degraded most efficiently apoB-100, induced LDL
fusion, and enhanced binding of LDL to isolated human aortic proteoglycans and human atherosclerotic
lesions ex vivo. Double immunofluoresence staining of human atherosclerotic coronary arteries for
tryptase and cathepsin G indicated that lesional MCs contain cathepsin G. In the lesions, expression of
cathepsin G correlated with the expression of tryptase and chymase, but not with that of neutrophil
proteinase 3.
Conclusions: The present study suggests that cathepsin G in human atherosclerotic lesions is largely
derived from MCs and that activated MCs may contribute to atherogenesis by enhancing LDL retention.
© 2018 Elsevier B.V. All rights reserved.1. Introduction
Atherogenesis is initiated at atherosclerosis-susceptible sites of
the arterial wall by focal retention of LDL particles within the
subendothelial extracellular matrix (ECM), particularly via binding
of LDL to proteoglycans (PGs) [1]. Indeed, the atherogenicity of LDL
is directly linked to its affinity for arterial wall PGs [1e3], which is
related to either the properties of LDL or the PGs. The PGeLDLtute, Biomedicum Helsinki,
inka, et al., Human mast cel
), https://doi.org/10.1016/j.athinteraction is ionic and takes place between clusters of positively
charged amino acid residues on apoB-100 and negatively charged
sulfate and carboxyl groups on the glycosaminoglycan chains of PGs
[4]. The principal site in apoB-100, which mediates the PG binding
of LDL spans the amino acid residues 3359e3369 (referred to as site
B) [2]. However, LDL particles seem to contain additional PG-
binding sites as indicated by identification of several regions in
apoB-100 that bind glycosaminoglycans, [5]; yet, these binding
sites may not be functionally available on native LDL particles [2].
Importantly, various modifications of LDL particles have been
shown to increase the binding of LDL to PGs [6e8], implying that
additional PG-binding sites may become functional when LDL isl neutral proteases generate modified LDL particles with increased
erosclerosis.2018.04.016
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In the arterial intima, LDL particles are subjected to various
structural and conformational modifications that promote the for-
mation of LDL-derived lipid droplets and vesicles in the sub-
endothelial extracellular space [7]. Such extracellular lipid particles
isolated fromhuman atherosclerotic lesions have features revealing
that the apoB-100-containing plasma lipoproteins, which have
entered the subendothelial space, have been exposed to proteolysis
and lipolysis [11]. Indeed, atherosclerotic lesions contain several
proteases capable of hydrolyzing the apoB-100 of LDL in vitro,
including both plasma-derived and locally synthesized proteases.
To the former group belong plasmin, kallikrein, and thrombin, and
to the latter group the lysosomal proteases cathepsins D, F, K, and S
secreted by intimal macrophages and smooth muscle cells of the
lesions [6,12e14].
An additional source of proteolytic enzymes in the arterial in-
tima are mast cells (MCs). This type of inflammatory cell is present
in both early and advanced human atherosclerotic lesions [15e17].
The cytoplasm of MCs is filled with secretory granules, which
contain high amounts of various neutral proteases [18]. All MCs in
atherosclerotic lesions contain tryptase, and a variable fraction
contain also chymase [15e17], both of which are virtually MC-
specific proteases [19]. A third major neutral granule protease of
MCs is carboxypeptidase A3 (CPA3), a zinc-dependent exopepti-
dase, which has previously been thought to be exclusively
expressed in MCs; however, more recently transcripts of CPA3 have
been found also in basophils [19]. In addition, human MC neutral
granule proteases include two serine proteases that are not unique
to this cell type, namely cathepsin G and granzyme B [20e22].
When MCs are activated, large amounts of the granule proteases
are released into the extracellular surroundings in a process called
degranulation. Unlike most other secreted proteases, the MC
granule proteases are stored in fully active form, and, thus, once
released they are capable of immediately triggering proteolytic
events in the extracellular microenvironment of the tissue inwhich
the activated MCs are present and degranulation occurs.
Recently, we developed a cell culture method for the differen-
tiation of mature MCs from their circulating progenitor cells [23],
and showed that mature MCs expressed a wide spectrum of the
known MC neutral proteases, namely the tryptases derived from
the TPSAB1, TPSB2, TPSD1, and TPSG1/PRSS31 genes, and chymase,
CPA3, cathepsin G, and granzyme B [21]. In the present study, we
investigated the ability of these neutral proteases to cleave apoB-
100 of LDL, and determined the effects of such proteolysis on the
binding of LDL to human aortic PGs.
2. Materials and methods
2.1. Cell preparation and culture
Human MCs were in vitro differentiated from buffy coats of
healthy volunteers, as previously described [23]. The buffy coats
were supplied by the Finnish Red Cross Blood Service (Helsinki,
Finland) with the approval of the Ethics Committee of the Finnish
Red Cross.
2.2. Preparation of mast cell-conditioned medium (mast cell
releasate)
At week 9 of culture, MCs at a concentration of 2 106MCs/ml
were activated by 1 mM calcium ionophore A21387 (Sigma-Aldrich)
in Dulbecco's phosphate buffered saline (DPBS) in a humidified
incubator at 37 C (5% CO2). After 30min of incubation, the MCs
were sedimented, and the supernatant containing the released
neutral proteases, i.e the MC-conditioned medium, which will bePlease cite this article in press as: K. Maaninka, et al., Human mast ce
proteoglycan binding, Atherosclerosis (2018), https://doi.org/10.1016/j.athreferred to as the MC releasate, was collected and stored at 80 C
until further analysis.
2.3. Protease activity assays and protease inhibitors
The amounts of active neutral proteases in MC releasates were
determined through hydrolysis of specific protease substrates, as
previously described [21]. In some experiments, some of the pro-
teases in the MC releasates were inhibited as follows: tryptase with
200 mg/ml leupeptin (Sigma-Aldrich), chymase with 670 nM
diphenyl Na-benzoxycarbonyl-L-Arg-Glu-Thr-PheP-phosphonate
[(RETF-(OPh)2] generously provided by Dr Gunnar Pejler (Uppsala
University, Uppsala, Sweden), and CPA3 with 1 ml/100 ml Carboxy-
peptidase Inhibitor from potato tuber (Sigma-Aldrich).
2.4. Preparation of human aortic proteoglycans
PGs from the intima-media of human aortas were obtained at
autopsy within 24 h of accidental death and prepared as described
previously [24,25]. The Finnish National Authority for Medicolegal
Affairs had approved the study. The amounts of the PGs are
expressed in terms of their glycosaminoglycan content, as deter-
mined by the method of Bartold and Page [26].
2.5. Isolation and modifications of LDL
Human LDL (d¼ 1.019e1.050 g/ml) were isolated from plasma
of healthy volunteers (supplied by the Finnish Red Cross Blood
Service) by sequential ultracentrifugation in the presence of 3mM
EDTA, as described [27,28]. The amount of LDL is expressed in terms
of its protein content determined by the method of Lowry and/or
BCA Protein Assay Kit (Thermo Scientific), with bovine serum al-
bumin as standard. MC protease-modified LDL was prepared by
incubation of LDL (1 or 2mg/ml) either with MC releasate, or
separately with 1.5 mg/ml recombinant human chymase (Sigma-
Aldrich), 20 mg/ml recombinant human b-tryptase (a kind gift from
Dr. Christian Sommerhoff), 4.5 mg/ml cathepsin G from human
neutrophils (Biomol), 10 mg/ml CPA from bovine pancreas (Sigma-
Aldrich), or 0.1 mg/ml granzyme B (QuickZyme Biosciences) in DPBS
overnight at 37 C. The protease concentrations were chosen based
on those found in the MC releasates. In some experiments, the
apoB-100 of LDL was labeled before treatment with MC neutral
proteases with a 3H-labeling reagent (t-butoxycarbonyl-L-[3H]
methionine N-hydroxy-succinimidyl ester [Amersham Bio-
sciences]) according to the Bolton-Hunter procedure [29].
The degree of apoB-100 proteolysis was determined by
measuring the amount of radioactive peptides released from the
LDL particle using the trichloroacetic acid (TCA) precipitation
method [30], or by measuring the amount of immunoreactive
apoB-100 with apoB ELISA (Mabthech) according to the manufac-
turer's instructions. SDS-PAGE was performed under denaturing
conditions using Novex Bolt Bis-Tris Plus 4e12% precast minigels
and Bolt MES-SDS Running buffer (both Invitrogen, Thermo Fisher
Scientific) according to the manufacturer's instructions. The extent
of oxidation of LDL was determined by measuring the amount of
thiobarbituric acid reactive substances (TBARS) [31].
In some experiments plasma of three healthy donors was
pooled prior to LDL isolation. The pooled LDL (1mg/ml) was then
incubated overnight with the recombinant human chymase (1.5 mg/
ml) or with cathepsin G (4.5 mg/ml) in the presence of human aortic
PGs (100 mg/ml), after which cleavage of apoB-100 of LDL was
visualized by SDS-PAGE. Finally, a fraction of the pooled LDL was
conjugated with Atto 594 N-Hydroxysuccinimide (NHS) ester
fluorochrome (Sigma Aldrich), as previously described [32], with
the exception of using 0.2M NaHCO3.ll neutral proteases generate modified LDL particles with increased
erosclerosis.2018.04.016
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Wells of 96-well plates were coated with 100 ml of PGs dissolved
in DPBS (at 25 mg/ml) by incubation at 4 C overnight. Thereafter,
the wells were blocked with 250 ml of buffer containing 3% BSA, 1%
fat-free milk, and 0.05% Tween-20 in DPBS for 60min at 37 C. Non-
coatedwells incubatedwith blocking buffer only served as controls.
After washing of thewells, 2 mg LDL that had beenmodifiedwith
MC releasate, or alternatively with individual neutral proteases,
was added to the wells in a total volume of 100 ml of buffer con-
taining 50mM Hepes, 150mM NaCl, 10mM CaCl2, and 10mM
MgCl2 (pH 7.5), and incubated for 60min at 37 C. After incubation,
unbound LDL particles were removed by washing the wells with
10mM Hepes buffer containing 50mM NaCl, 2mM CaCl2, and
2mM MgCl2, and the amounts of bound LDL particles in the wells
were determined using the Amplex Red Cholesterol assay kit
(Invitrogen, Thermo Fisher Scientific) according to the manufac-
turer's instructions. Specific binding to PGs was calculated by
subtracting the amount of LDL bound to the non-coated wells from
the amount of LDL bound to the PG-coatedwells, and the results are
expressed as fold change relative to native LDL.
2.7. Ex vivo binding of LDL to human carotid atherosclerotic lesions
Frozen tissue sections (10 mm) were cut from OCT (Tissue-Tek
O.C.T. compound, Sakura) embedded carotid artery and stored
at 20 C until used. Human LDL, both atto 594-labeled LDL and
non-labeled, was dialyzed against sample buffer [50mM Hepes
buffer containing 30mM NaCl, 2mM MgCl2 and 2mM CaCl2 (pH
7.5)], after which the LDL samples (1mg/ml) were incubated in the
presence or absence of 4.5 mg/ml cathepsin G overnight at 37 C.
OCT from the frozen tissue sections was removed by incubating the
slides in DPBS for 20min at room temperature, after which the
slides were quickly rinsed with H2O. In some cases, the tissue
sections were pre-incubated for 60min at 37 C with 50 mU
chondroitinase ABC (Amsbio, former Seikagaku) in 50mM Tris
buffer containing 50mM sodium acetate and 0.01% BSA (pH 8.0).
The slides were then washed twice with sample buffer and incu-
bated with the LDL samples (0.3mg/ml in sample buffer) for
90min at 37 C in a humidified chamber. The tissue sections were
washed three times with sample buffer, quickly rinsed with H2O,
and finally mounted with Vectashield fluorescent mounting media
with DAPI (Vector Laboratories). The images were acquired using
Leica DM6000 microscope equipped with DFC420 camera and LAS
AF (Leica Application Suite Advanced Fluorescence) software (Leica
Microsystems).The differences in PG-binding between native atto
594-labeled LDL and cathepsin G-treated atto 594-labeled LDL
were judged based on fluorescence intensities quantified using
Image J software (NIH). Unlabeled LDL, both native and cathepsin
G-treated, was used as negative control.
2.8. Circular dichroism spectroscopy
After incubation overnight with chymase, cathepsin G or MC
releasate, samples of LDL (50 mg/ml) were analyzed by circular di-
chroism (CD) as described previously [33]. Before analyses, the
neutral proteases were separated from LDL by extensive centrifu-
gation (40 000 rpm, 2 h at 4 C).
2.9. Electron microscopy
LDL particles were negatively stained using 2% neutral uranyl
acetate, inspected under a Jeol JEM-1400 transmission electron
microscope (Jeol Ltd., Tokyo, Japan) and photographed with Gatan
Orius SC 1000B camera (Gatan Inc., Pleasanton, CA, USA) at thePlease cite this article in press as: K. Maaninka, et al., Human mast cel
proteoglycan binding, Atherosclerosis (2018), https://doi.org/10.1016/j.athElectron Microscopy Unit, Institute of Biotechnology, University of
Helsinki. The diameters of 100e250 randomly selected lipoprotein
particles were measured with Image Pro Plus software, version 6.2
(Media Cybernetics, Inc., Rockville, MD, USA) from the electron
micrographs.
2.10. Coronary and carotid samples
Human coronary artery specimens for immunohistochemistry
and quantitative PCR were selected fromWihuri Research Institute
coronary specimen collection [34,35]. Samples were either from
patients that underwent heart transplant surgery (n¼ 1 for
immunohistochemistry and n¼ 4 for RNA isolation, collected after
informed consent of the patients) or from heart transplant donors
(n¼ 5 for RNA isolation) collected for research purposes in cases in
which the candidate heart transplant did not fulfil the criteria for
clinical use. The coronary tissue pieces had been snap-frozen in
liquid nitrogen and stored at 80 C (RNA isolation) or fixed
(immunohistochemistry) immediately after the excision. Human
carotid atherosclerotic plaques were obtained from patients un-
dergoing carotid endarterectomy operation in the Department of
Vascular Surgery in Helsinki University Hospital after informed
consent from the patients. The carotid tissue pieces had been snap-
frozen in liquid nitrogen and stored at80 C until further analysis.
The use of human material conforms to the principles outlined in
the Declaration of Helsinki and the study protocol was approved by
the responsible Ethics Committees of the Helsinki University Hos-
pital or the Finnish National Authority for Medicolegal Affairs.
2.11. Immunohistochemistry of human coronary atherosclerotic
plaque
For immunohistochemical studies the coronary segments were
treated and double immunostained against cathepsin G and tryp-
tase, as described previously [34], except that cathepsin G was
visualized with goat anti-rabbit IgG Alexa 488 (1:200, green) and
tryptase with goat anti-mouse IgG1Alexa 546 (1:200, red, Molec-
ular Probes). The numbers of tryptase-positive and cathepsin G-
positive cells were counted using Image J software (NIH).
2.12. RNA isolation from human coronary arteries and quantitative
PCR
RNA was isolated from snap-frozen coronaries as previously
described [35]. cDNA was synthesized from coronary RNA with
High-Capacity cDNA Reverse Transcription Kit according to in-
structions of themanufacturer (Applied Biosystems). The cDNAwas
amplified in duplicates and the data were calculated as previously
described [21] using the following gene-specific primers and
probes: cathepsin G (CTSG) 50-GGTTCCTGGTGCGAGAAGAC-3’
(sense), 50-GATGTGTTGCTGGGTGTTTTC-3’ (anti-sense), and 50-
AAGCAATATAAATGTCACCCTGGGCGC-3’ (probe); chymase (CMA1)
50-TGCTCATTGTGCAGGAAGGTC-3’ (sense) and 50-
ACCTCAAGCTTCTGCCATGTG-3’ (anti-sense); tryptase (TPSAB1/
TPSB2) 50-CGATGTGGACAATGATGAGC-3’ (sense) and 50-
CGCCAAGGTGGTATTTTGC-3’ (anti-sense); CD68 50-AGCTTTGGATT-
CATGCAGGAC-3’ (sense) and 50-ATCTCGAAGGGATGCATTCTG-3’
(anti-sense); and proteinase 3 (PRTN3) 50-TGTCACCGTGGT-
CACCTTCTT-3’ (sense), 50-CCCCAGATCACGAAGGAGTCTAT-3’ (anti-
sense), and 50-TTGCACTTTCGTCCCTCGCCG-3’ (probe). Target gene
expression was normalized to glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) [50-CCACATCGCTCAGACACCAT-30 (sense), 50-
GGCAACAATATCCACTTTACCAGAG-30 (anti-sense), and 50-CCAA-
TACGACCAAATCCGTTGACTCC-30 (probe)].l neutral proteases generate modified LDL particles with increased
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Statistical analyses were performed with the GraphPad Prism
software, version 6 (GraphPad Software, Inc., La Jolla, CA, USA) and
SPSS for Windows software, version 20 (SPSS Inc., Chicago, Illinois,
USA) using the nonparametric Kruskall-Wallis test with Dunn's
multiple comparisons correction to compare the groups. p< 0.05
was considered statistically significant. Correlations were investi-
gated by calculation of Pearson's coefficient of correlation. The data
in the figures are expressed as means± SEM.
3. Results
3.1. Activated mast cells release a variety of neutral proteases
At week 9 of culture, human MCs were activated with calcium
ionophore to degranulate, and thereby to release their neutral
granule proteases into the incubation medium. The amounts of the
released enzymatically active proteases were then measured by
activity assays using protease-specific substrates and/or inhibitors.
The conditioned media, i.e. MC releasates contained 11.2± 5.8 mg/
ml of tryptase, 1.3± 0.4 mg/ml of chymase, 3.2± 1.2 mg/ml of
cathepsin G, and 0.09± 0.1 mg/ml of granzyme B (n¼ 5 donors in
duplicate experiments).
3.2. Cathepsin G is the major apoB-100-degrading neutral protease
of cultured human mast cells
LDL was first incubated overnight with each of the neutral
proteases present in MC releasate, after which the degree of pro-
teolysis of apoB-100 was determined by TCA-precipitation, apoB-
100 ELISA, and SDS-PAGE. Treatment of LDL with the proteases
resulted in proteolysis of apoB-100 at various degrees, as indicated
by the release of small TCA-soluble apoB-100-derived peptides
from the protease-treated LDL particles (Fig.1A). The percentages of
TCA-soluble fragments produced after treatment of LDL with the
various proteases at concentrations found in the MC releasates
revealed that cathepsin G led tomost extensive proteolysis of apoB-
100 (12.9± 0.9%), followed by chymase (4.2± 0.1%), tryptase
(3.3± 0.1%), and CPA (2.5± 0.3%). Of note, granzyme B was practi-
cally unable to fragment apoB-100 into small TCA-soluble peptides.
MC releasate containing all the above mentioned neutral proteases
resulted in the generation of 6.8± 0.5% TCA-soluble fragments.
However, when all proteases, except with cathepsin G, had been
inhibited with specific inhibitors, MC releasate resulted in more
extensive proteolysis (about 10.7± 2.3% TCA-soluble fragments), a
finding in line with the results obtained with purified cathepsin G.
Of note, the peptidic inhibitor, RETF-(OPh)2, specifically inhibits
chymase, while allowing full activity of cathepsin G [36], and was
thus used to selectively inhibit chymase in MC releasates. ApoB
ELISA, that specifically detected apoB-100 but not apoB-48, indi-
cated that, depending on the neutral protease used, treatment of
LDL with MC neutral proteases induced loss of C-terminal immu-
noreactivity of apoB-100 at various degrees (Fig. 1B). Importantly,
incubation of LDL with cathepsin G resulted in almost total loss of
the apoB-100 C-terminal immunoreactivity.
The cleavage patterns of apoB-100 by MC releasate, tryptase,
chymase, and cathepsin G were visualized with SDS-PAGE. As
shown in Fig. 1C and D, incubation of LDL with humanMC releasate
led to extensive degradation of apoB-100. Comparison of the apoB
bands formed after incubation of LDL with tryptase, chymase, or
cathepsin G showed that each neutral protease generated a specific
cleavage pattern of apoB-100. CPA3 and granzyme B were excluded
from this experiment because CPA3, as an exopeptidase only
cleaves the C-terminal amino acid, and granzyme B, again,Please cite this article in press as: K. Maaninka, et al., Human mast ce
proteoglycan binding, Atherosclerosis (2018), https://doi.org/10.1016/j.athappeared not to degrade apoB-100, when examined with the TCA-
assay and apoB-100 ELISA, as described above. The presence of PGs
in the LDL incubation mixtures clearly affected the cleavage pattern
of apoB-100 generated by cathepsin G, whereas their presence
appeared not to have a significant effect on the chymase-dependent
cleavage pattern of apoB-100 (Fig. 1D). In fact, the cleavage pattern
of apoB-100 treated by cathepsin G in the presence PGs resembled
that generated by MC releasate.
3.3. Cathepsin G- and mast cell releasate-dependent proteolysis of
LDL increases its binding to proteoglycans
PG-binding of native and modified LDL was determined by in-
cubation of the LDL samples with isolated human aortic PGs, and
measuring the amount of cholesterol of the bound LDL with
Amplex Red cholesterol assay. Treatment of LDL with MC releasate
increased the binding of LDL to human aortic PGs by almost 4-fold
compared with native LDL (Fig. 2A). Similar fold increase in PG-
binding was also observed when LDL was treated with cathepsin
G, whereas treatment of LDL with chymase increased the PG-
binding by 2-fold. In contrast, treatment of LDL with tryptase
generated LDL particles with significantly decreased PG-binding,
when compared with untreated LDL particles. The binding of LDL
to human atherosclerotic plaques was evaluated by incubating
fluorescently labeled LDL, both native and cathepsin G-treated with
frozen tissue sections of human carotid plaques. We found that
treatment of LDL with cathepsin G increased remarkably the
binding of LDL to the plaques, as indicated by differences in the
fluorescence intensities (Fig. 2B and C). Furthermore, enzymatic
digestion of chondroitin sulfate caused a drastic reduction in the
binding of the cathepsin G-treated LDL (Fig. 2C and D), indicating
that chondroitin sulfates of the extracellular matrix play an
important role in mediating the binding of LDL to the atheroscle-
rotic plaques. Unlabeled LDL used as a negative control is shown in
Fig. 2E.
3.4. Cathepsin G-dependent proteolysis of LDL induces
conformational changes in apoB-100
To study the effect of LDL proteolysis on secondary structure of
apoB-100, conformational changes of apoB-100 was analyzed by
circular dichroism. To exclude the contribution of CD of the neutral
proteases per se, LDL particles were first flotated by centrifugation
at 40 000 rpm, for 2 h, at 4 C, to separate the neutral proteases
from LDL. Compared to control LDL particles (Fig. 3A) the spectra of
proteolyzed LDL have similar shape but show a slight decrease in
CD intensity, indicating that proteolysis of LDL by MC proteases,
especially with cathepsin G resulted in conformational changes of
apoB-100. The difference between the CD spectra of native LDL and
of cathepsin G-treated LDL is shown in Fig. 3B.
3.5. Cathepsin G and mast cell releasate trigger fusion of LDL
particles
Proteolysis of apoB-100 has been shown to promote fusion of
LDL particles resulting in formation of enlarged particles [9,30]. The
effect of proteolysis on LDL particle fusion was examined using
transmission electron microscopy to produce electron micrographs
from which the diameters of negatively stained differentially
treated LDL particles were measured (Fig. 4A and B). The diameter
of the native LDL particles was 22.0± 0.40 nm. However, treatment
of LDL with MC releasate, cathepsin G, or chymase led to the for-
mation of enlarged (i.e., fused) LDL particles and to a more skewed
size distribution. Indeed, the diameters of LDL particles were
29.5± 0.70 nm, 30.3± 0.60 nm, and 27.0± 0.32 nm when LDL werell neutral proteases generate modified LDL particles with increased
erosclerosis.2018.04.016
Fig. 1. Proteolysis of apoB-100 of LDL by mast cell neutral proteases.
LDL was incubated overnight with various MC neutral proteases after which the degree of apoB-100 proteolysis was measured with TCA-sedimentation, apoB ELISA, and SDS-PAGE.
(A) Proteolysis of apoB-100 by the various MC neutral proteases is shown by the release from LDL particles of radioactively labeled TCA-soluble fragments of apoB-100. The data are
presented as percentage of TCA soluble radioactivity per total radioactivity (radioactivity in an identical sample, which was not precipitated with TCA). (B) Concentration of apoB-
100 in native LDL and LDL treated with MC neutral proteases after overnight incubation. The data is presented as fold change relative to apoB-100 in native LDL. (C) Degradation of
apoB-100 in LDL by MC releasate, chymase, and cathepsin G is visualized by SDS-PAGE. D) SDS-PAGE showing fragmentation pattern of apoB-100 after incubation of LDL with
cathepsin G and chymase in the presence and absence of human aortic PGs. The data in panel A are means ± SEM from two and in panel B from three independent experiments
prepared in duplicates with different LDL preparations. *p0.05; **p0.01;****p<0.0001.The figure in panel C is representative of three and in panel D of two individual experiments
with different LDL preparations. Cath G, cathepsin G; Chy, chymase; CPA, carboxypeptidase A; GrB, granzyme B; TCA, trichloroacetic acid; Try, tryptase. The LDL preparations
proteolyzed individually with the above-listed proteases are labeled using the above abbreviations as prefixes.
K. Maaninka et al. / Atherosclerosis xxx (2018) 1e10 5treated with MC releasate, cathepsin G, and chymase, respectively.
Fig. 4C shows the approximate diameters of particles generated by
fusion of 2e100 LDL particles, and based on this, the average-sized
fusion particle resulted from fusion of 2e3 LDL proteolyzed LDL
particles. The largest particles observed by electronmicroscopy had
diameters of about 100 nm and based on the calculations, they had
been generated when about 100 of the normal-sized 22-nm LDL
particles had fused to form a single particle.3.6. Mast cells are the major cathepsin G-positive type of cell in
atherosclerotic coronary plaques
To identify the presence of MCs in atherosclerotic lesions, sec-
tions of human coronary arterial plaque with histomorphological
characteristics of a stable plaque were immunostained against
cathepsin G and tryptase, the latter one indicating the presence of
MC. Representative double immunofluorescence staining of
cathepsin G and tryptase in a coronary plaque is presented in
Fig. 5AeD and shows the presence of cathepsin G-positive MCs in
the plaque. In fact, of all cathepsin G-positive cells 69% were MCs,
i.e. cathepsin G-positive tryptase-positive cells, a findingwhich is in
accordance with a previous study of our laboratory reporting thatPlease cite this article in press as: K. Maaninka, et al., Human mast cel
proteoglycan binding, Atherosclerosis (2018), https://doi.org/10.1016/j.athMCs represent, on average, 73% of all cathepsin G-positive cells in
human coronary plaques [34]. The plaque also contained some
cathepsin G-positive cells which were tryptase-negative, i.e., they
were not MCs. The tryptase-negative cathepsin G-positive cells
were not specified further.3.7. Cathepsin G expression correlates with mast cell tryptase and
chymase but not with neutrophil proteinase 3 in coronary plaques
To further evaluate the candidate cell types expressing
cathepsin G in atherosclerotic plaques, the expression of cathepsin
G, the MC-specific chymase and tryptase, neutrophil proteinase 3,
and CD68, the latter of which is mainly expressed by monocytes
and macrophages, but also by MCs, were analyzed both in coronary
segments of AHA classes I-II and in advanced atherosclerotic pla-
ques (AHA classes IV-V) from 9 patients [35]. We found a significant
correlation between the expression of lesional cathepsin G and the
MC chymase and tryptase, and to a lesser extent between lesional
cathepsin G and CD68, but not between cathepsin G and neutrophil
proteinase 3 (Fig. 5EeH). The data are presented as fold changes
relative to normal coronary segment of each patient.l neutral proteases generate modified LDL particles with increased
erosclerosis.2018.04.016
Fig. 2. Binding of modified LDL to human aortic proteoglycans and to human carotid atherosclerotic lesions.
A) Native and modified LDL was incubated with human aortic PGs, after which the amount of bound LDL was determined. The amount of PG-bound LDL is presented as the amount
of cholesterol per mg LDL protein. The data are expressed as fold change related to native LDL, the level of which was set to 1. The data are means ± SEM of two independent
experiments prepared as duplicates with different LDL preparations. *p0.05; **p0.01; ****p<0.0001. Retention of LDL in atherosclerotic lesions was analyzed by incubating
fluorescently labeled LDL with sections of human carotid atherosclerotic lesions. Bound LDL was detected using immunofluorescence microscopy, and fluorescence intensities of the
representative images were quantified to determine differences between differentially treated LDL. Binding of fluorescently labeled native LDL (B) and cathepsin G-treated LDL (C) to
tissue sections. (D) Binding of fluorescently labeled cathepsin G treated-LDL to tissue section pre-treated with chondroitinase. (E) Unlabeled LDL was used as a negative control.
Fluorescence intensities are shown in the upper right hand corner. Scale bars¼ 100 mm.
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In the present study, we investigated the proteolytic activity
towards apoB-100 of LDL of various neutral proteases known to be
present in the cytoplasmic secretory granules of human MCs,
namely tryptase, chymase, CPA3, cathepsin G, and granzyme B. The
present data demonstrate that cathepsin G efficiently degrades
apoB-100 of LDL, and that this enzyme is the major apoB-100-
degrading neutral granule protease in human MCs. Proteolysis of
LDL with cathepsin G led to increase both in the size and in the
binding of the proteolyzed LDL to isolated human aortic PGs andPlease cite this article in press as: K. Maaninka, et al., Human mast ce
proteoglycan binding, Atherosclerosis (2018), https://doi.org/10.1016/j.athPGs in human carotid atherosclerotic lesions ex vivo. Since athe-
rogenicity of LDL is linked to its ability to bind PGs [1], novel
mechanisms leading to increased PG binding of LDL are likely to
contribute to better understanding of the molecular bases behind
the pathogenesis of this disease.
Cathepsin G is a serine protease expressed in MCs and neutro-
phils [19]. In human MCs, cathepsin G is the closest relative of
chymase and it shares some functional properties with human
chymase, such as the ability to convert angiotensin II from angio-
tensin I [37]. Similar to chymase, cathepsin G has a chymotrypsin-
like activity, that is, a preference of cleaving peptide and proteinll neutral proteases generate modified LDL particles with increased
erosclerosis.2018.04.016
Fig. 3. Conformational changes in the secondary structure of apoB-100 upon proteolysis of LDL.
(A) Far UV CD spectra of apoB-100 in native LDL and LDL treated overnight with MC releasate, or alternatively with cathepsin G or chymase. Five spectra for each sample were
averaged, and blank measurements were subtracted. Data are representative of two independent experiments. (B) Spectrum difference between LDL and cath G-modified LDL: [Ɵ]
LDL - [Ɵ] cath G-modified LDL. UV, ultraviolet; CD, circular dichroism.
Fig. 4. Size distribution of differentially modified LDL particles.
(A) LDL particles, both native and modified (either with MC releasate, or with cathepsin G, or chymase) were negatively stained and examined with electron microscopy, after which
the size distributions of the particles were determined by measuring the diameters of 100e250 particles from each photograph. Scale bars ¼ 50 nm. The size distribution of each
sample is shown in the scatter plot histogram. The horizontal line in each box represents the median of the measured values. (B) Representative electron micrographs of differ-
entially treated LDL particles. (C) The relationship between the number of LDL particles fused to form a single fusion particle and the diameter of the corresponding fusion particle.
*p0.05; ***p0.001; ****p<0.0001.
K. Maaninka et al. / Atherosclerosis xxx (2018) 1e10 7substrates at the C-terminal site of aromatic amino acids, such as
phenylalanine, tyrosine, and tryptophan. However, compared to
chymase it has a broader cleavage specificity by possessing, in
addition to chymotrypsin-like activity, also trypsin-like activity
[38]. This is likely to explain the more potent destructive potential
of cathepsin G compared with chymase towards apoB-100.
Studies of human subjects have provided evidence that
cathepsin G expression in the arterial wall increases during
atherogenesis. Thus, when compared with normal human aortas,
the expression of cathepsin G and chymase in atherosclerotic aortas
was found to be increased [39]. In line with the above observation,
human atherosclerotic lesions have been shown to contain signif-
icantly higher numbers of cathepsin G-positive MCs compared to
control vessels [40]. In a previous immunohistochemical study [34],
we compared the proportions of two cathepsin G-containing cells,
MCs and neutrophils, in atherosclerotic lesion of human coronary
artery, and found a MC-to-neutrophil ratio of 5: 1. Although
cathepsin G has been mainly associated with these two cell types,
in human carotid atherosclerotic lesions also macrophages, smooth
muscle cells, CD31-positive endothelial cells, and CD4 Tcells appearPlease cite this article in press as: K. Maaninka, et al., Human mast cel
proteoglycan binding, Atherosclerosis (2018), https://doi.org/10.1016/j.athto contain cathepsin G [41]. Yet, in accordance with the previous
finding [34], we now found that in human coronary atherosclerotic
lesions most cathepsin G-containing cells also contained the MC-
specific neutral protease tryptase and that the expression of
cathepsin G correlates remarkably with the expression of chymase
and tryptase, but not with neutrophil proteinase 3, findings indi-
cating that MCs are a major local source of cathepsin G in human
atherosclerotic lesions, at least in the stable phase of the disease.
Interestingly, cathepsin G activity in the circulating blood has an
LDL-lowering effect, which was found to be associated with
reduced atherosclerosis in experimental animals, and was sug-
gested to possess a protective effect against atherosclerosis also in
humans [41]. It is worth noting that MCs are found in circulation
only as agranular progenitor cells and accumulate cathepsin G and
other neutral granule proteases only during differentiation in pe-
ripheral tissues [21]. Thus in the bloodstream, neutrophils appear
to represent the major cathepsin G-containing cell type. In the
circulating blood, cathepsin G on neutrophil surface remains active,
and may so degrade the apoB-100 component of LDL, thereby
modifying the particles to be cleared more rapidly by, e.g. the liver,l neutral proteases generate modified LDL particles with increased
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Fig. 5. Expression of cathepsin G, tryptase, chymase, proteinase 3, and CD68 in human coronary artery specimens.
The double immunofluorescence staining shows cellular localization of tryptase (A) and cathepsin G (B) in shoulder region of an atherosclerotic plaque in human coronary artery.
Nuclei were stained with DAPI (C). Colocalization of tryptase and cathepsin G is shown in panel D. 20 objective. (E-H) Expressions of cathepsin G, chymase, tryptase, neutrophil
proteinase 3, and CD68 genes were analyzed from atherosclerotic coronary segments obtained from 9 patients. The data are presented as fold changes relative to normal coronary
segment of each patient. Correlation of the expression of cathepsin G with that of (E) chymase, (F) tryptase, (G) proteinase 3, and (H) CD68 are shown.
K. Maaninka et al. / Atherosclerosis xxx (2018) 1e108and so reducing exposure of the arterial wall to circulating LDL
particles. In sharp contrast, the apoB-100edegrading activity of
cathepsin G in the arterial intima appears to be solely pro-
atherogenic, and based on the previous [34] and the present data,
highly attributed to MCs.
In the context of cardiovascular diseases, cathepsin G is best
known for its angiotensin-converting activity [37]. In addition,
cathepsin G activates matrix metalloproteinases [42e44] that have
been shown to participate in atherogenesis [45], and may degrade
VE-cadherin [34], an important structural component for the
integrity of the arterial endothelium. Cathepsin G is also involved in
monocyte and neutrophil chemotaxis [46]. Interestingly, studies
using genetically modified Apoe/and CatG/- mice showed that
cathepsin G controls arterial, but not venous, myeloid cell recruit-
ment, and lack of cathepsin G protected the mice from athero-
sclerosis [47]. By showing that cathepsin G efficiently degrades
apoB-100 of LDL with ensuing increase in PG-binding of the pro-
teolyzed LDL, the present study adds a novel mechanism by which
cathepsin G may contribute to atherogenesis.
Initially it was found that secretory granules exocytosed from rat
MCs degradade apoB-100 in LDL particles [48]. Subsequent studies
showed that heparin present in the exocytosed rat MC granules is
capable of binding apoB-100 of LDL [49], thus facilitating proteol-
ysis of apoB-100 by the, also granule-bound, chymase and CPA [50].
The sequential proteolysis of apoB-100 by the two neutral pro-
teases resulted in fusion of LDL particles with ensuing formation of
larger lipoprotein particles on MC granules [51]. Importantly, both
proteolysis and fusion of the rat granule etreated LDL particles
were found to contribute to increased binding of LDL to the heparin
glycosaminoglycan chains of the granule PGs [52]. It is likely that
proteolysis of apoB-100 on the surface of the modified LDL particles
induces conformational changes in it, thereby increasing its ability
to interact with PGs. In the present study, proteolysis of LDL withPlease cite this article in press as: K. Maaninka, et al., Human mast ce
proteoglycan binding, Atherosclerosis (2018), https://doi.org/10.1016/j.athcathepsin G was associated with conformational changes in the
secondary structure of apoB-100, which may have exposed cryptic
domains for PG binding [9], such as the residues 3148e3158
(referred to as site A) that becomes exposed in phospholipase A2-
modified LDL resulting in increased PG-binding of the phospholi-
pase A2-treated LDL [10]. In the present study, tryptase treatment
nearly completely abolished the binding of LDL to PGs. A reasonable
explanation for this observation is that tryptase-induced frag-
mentation of apoB-100 leads to conformational changes in it, and
that they block the main PG-binding site of apoB-100.
Proteolysis-induced fusion of LDL requires release of apoB-
fragments from LDL particles [30]. ApoB-100 covers about 1/3 of
LDL surface and proteolytic removal of parts of this protein is
thought to lead to loosening of the surface lipid monolayer of the
modified particles followed by their destabilization and fusion
[7,53]. In the present study, we show that proteolysis of LDL with
cathepsin G or chymase or with MC releasate leads to release of
apoB-fragments from the modified LDL and increases the size of
LDL particles from approximately 22 nm to 30 nm, thus resulting in
the formation of enlarged LDL particles that fall within the range of
the extracellular lipid particles in the human atherosclerotic arte-
rial intima [11,54]. Particle fusion may induce an increase in PG-
binding strength due to an increase in the total number of
exposed positively charged domains, i.e., of potential PG-binding
sites, on the surface of modified LDL, as also previously suggested
[9]. Indeed, as proteolytic fusion of LDL leads to accumulation of
non-releasable apoB-100 fragments of several proteolyzed LDL
particles in a single fused LDL particle, formation of large particles
with multiple copies of PG-binding sites may ensue [9]. Since
cathepsin G-, chymase-, and MC releasate-modified LDL particles
showed signs of fusion, the above-described mechanism may
partially explain the increased PG-binding of these particles. Taken
together, proteolytic fusion provides a plausible mechanism byll neutral proteases generate modified LDL particles with increased
erosclerosis.2018.04.016
K. Maaninka et al. / Atherosclerosis xxx (2018) 1e10 9which cathepsin G and chymase released by activated mast cells
induce degradation of apoB-100 and increase the PG-binding of the
modified LDL, yielding LDL particles with potent atherogenic
properties.
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